Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Curator's Cut: Soft Commodities' Hard Truths, Pricing China's Hi-Tech & Sumitomo Pharma's Placement

Sumitomo Pharma (4506 JP): Placement Is In Line With “Boost 2028” Plan, R&D in Focus

Sumitomo Pharma (4506 JP): America Drives FY26, To Be Continued in FY27, Enzomenib in Pivotal Phase

2026 High Conviction Update: Sumitomo Pharma (4506 JP): Key Drugs Shine; FY26 Guidance Reiterated

Sumitomo Pharma (4506 JP): Guidance See Upward Revision as Orgovyx, Gemtesa Gain Momentum in H1FY26

2026 High Conviction: Sumitomo Pharma (4506 JP) – Enzomenib Progress and Reboot Strategy Hold Key

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sumitomo-pharma-co" target="_blank" data-smartkarma-citation="entities:1935:1" rel="noopener">Sumitomo Pharma (4506 JP)</a> revised its consolidated financial forecasts for FY26, which were announced on October 31, 2025.</li>
<li>Revenue has been revised upward by ¥20B to ¥449B, reflecting higher sales of products such as Gemtesa in the North America segment, as well as positive impact of weaker yen.</li>
<li>Sumitomo Pharma has filed the shelf registration statement regarding the issuance of new shares. The scheduled amount of issuance will not be more than ¥140B.</li>
</ul>



Sumitomo Pharma (4506 JP) revised its consolidated financial forecasts for FY26, which were announced on October 31, 2025.
Revenue has been revised upward by ¥20B to ¥449B, reflecting higher sales of products such as Gemtesa in the North America segment, as well as positive impact of weaker yen.
Sumitomo Pharma has filed the shelf registration statement regarding the issuance of new shares. The scheduled amount of issuance will not be more than ¥140B.


2026 High Conviction Update: Sumitomo Pharma (4506 JP): Guidance Revised, “Boost 2028” Plan Unveiled